News topic
Analysis News & Updates
Interpretive coverage connecting research, regulatory, and market signals into broader trends.
6 articles in this topic
VK2735: The Oral Weight Loss Pill Showing 12% Loss in 13 Weeks
Viking Therapeutics' VK2735 just posted Phase 2 data that has the obesity drug world paying attention: an oral pill that produced 12.2% weight loss in 13 weeks — without injections. If Phase 3 confirms these results, VK2735 could become the first oral dual GLP-1/GIP agonist to reach the market, competing directly with Ozempic and Zepbound.
Nature Asked If the Peptide Craze Is Backed by Science. Here's What the Evidence Actually Shows.
Nature's June 2026 investigation into the peptide trend found that "enthusiasm has got ahead of the science." With Google searches for peptides hitting 8 million per month — up from 1.3 million in 2024 — the gap between marketing claims and clinical evidence has never been wider. Here's our analysis of what Nature got right, what they missed, and what it means for anyone considering peptide therapy.
Ozempic vs Mounjaro vs Retatrutide: Which Weight Loss Drug Wins in 2026?
Three drugs now dominate the weight loss landscape: Ozempic/Wegovy (semaglutide), Mounjaro/Zepbound (tirzepatide), and the upcoming retatrutide. Each produces dramatic weight loss through different mechanisms. This analysis compares them on the metrics that actually matter — efficacy, side effects, cost, and practical considerations.
Natural Alternatives to Ozempic: Do Any Peptides or Supplements Actually Work?
With Ozempic costing $1,000+/month and carrying GI side effects, many people are searching for natural alternatives. We reviewed the evidence on peptides, supplements, and lifestyle interventions that target similar appetite and metabolic pathways — and separated the science from the marketing.
Peptide Therapy Cost Breakdown 2026: What You Will Actually Pay
Peptide therapy pricing varies enormously based on compound, source, and delivery model. This is a transparent breakdown of what patients actually pay in 2026, from $20/month sermorelin to $1,300/month retatrutide-class drugs.
Semaglutide Microdosing: The 2026 Trend, Benefits & Risks Explained
Semaglutide microdosing — using 0.1-0.25 mg weekly instead of the standard 2.4 mg — has exploded in popularity in 2026. Does the research support it, or is it a trend built on anecdote?